Advertisement

Topics

FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer

15:02 EST 14 Feb 2018 | Drugs.com

February 14, 2018 -- The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone...

Original Article: FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Erleada (apalutamide) for Non-Metastatic Castration-Resistant Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...